MediWound Revenue Jumps 43% in Q2
MediWound ( NASDAQ:MDWD ) reported fiscal second quarter 2025 results on Aug. 14, 2025, with revenue rising 43% quarter over quarter to $5.7 million, driven by higher product sales and a favorable mix. The company advanced its Phase III EscharEx VALUE trial, expanded NexoBrid's U.S. presence, and ...
MediWound ( MDWD ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 14, 2025 at 8:30 a.m. ETChief Executive Officer - Ofer GonenContinue reading ...
Vericel Q2 Revenue Jumps 20%
Vericel ( NASDAQ:VCEL ) , a cell therapy specialist focused on sports medicine and burn care, reported its Q2 2025 results on July 31, 2025. The most headline-worthy news was the 20% year-over-year GAAP revenue growth, driven strongly by its MACI franchise, and a substantial gross margin gain to ...
Vericel Corporation ( VCEL ) Reports Q2 Loss, Lags Revenue Estimates
Vericel (VCEL) delivered earnings and revenue surprises of +75.00% and -1.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Vericel Reports Second Quarter 2025 Financial Results
Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million ...
Wave Life Sciences ( WVE ) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.90% and -31.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MediWound ( MDWD ) Q1 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, May 21, 2025, at 8:30 a.m. EDTChief Executive Officer - Ofer GonenContinue reading ...
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned ...
Vericel Corporation ( VCEL ) Reports Q1 Loss, Misses Revenue Estimates
Vericel (VCEL) delivered earnings and revenue surprises of -155.56% and 2.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
CAMBRIDGE, Mass., May 07, 2025 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Bank of America Securities 2025 Healthcare Conference at 12:20 p.m.
Halozyme Therapeutics ( HALO ) Surpasses Q1 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 16.84% and 10.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Travere Therapeutics ( TVTX ) Reports Q1 Loss, Tops Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of 14.55% and 3%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025
CAMBRIDGE, Mass., April 24, 2025 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025.
Beta Bionics Announces Board Appointment of Gerard Michel - Beta Bionics ( NASDAQ:BBNX ) , Delcath Systems ( NASDAQ:DCTH )
IRVINE, Calif., March 27, 2025 ( GLOBE NEWSWIRE ) -- Beta Bionics, Inc. BBNX, a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025.
Beta Bionics Announces Board Appointment of Gerard Michel
IRVINE, Calif., March 27, 2025 ( GLOBE NEWSWIRE ) -- Beta Bionics, Inc. ( Nasdaq: BBNX ) , a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, ...
Vericel to Present at Multiple Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2025 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences: ...
Vericel Corporation ( VCEL ) Tops Q4 Earnings Estimates
Vericel (VCEL) delivered earnings and revenue surprises of 26.67% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of ...
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Applied Digital ( NASDAQ:APLD ) , Alvotech ( NASDAQ:ALVO )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday. Shares of Applied Digital Corporation APLD fell sharply in today's pre-market trading following second-quarter results.
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 - Vericel ( NASDAQ:VCEL )
CAMBRIDGE, Mass., Jan. 08, 2025 ( GLOBE NEWSWIRE ) -- Vericel Corporation VCEL, a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET ( 7:30 a.m.
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
EscharEx IND Submission by Year-End. Phase 3 Study to Begin Shortly Thereafter. KOL Event Set for January ...
Vericel Corporation ( VCEL ) Reports Q3 Loss, Tops Revenue Estimates
Vericel (VCEL) delivered earnings and revenue surprises of 60% and 4.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Prothena ( PRTA ) : Can Its 15.0% Jump Turn into More Strength?
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024
CAMBRIDGE, Mass., Oct. 24, 2024 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7, 2024.
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024 - Vericel ( NASDAQ:VCEL )
CAMBRIDGE, Mass., Aug. 29, 2024 ( GLOBE NEWSWIRE ) -- Vericel Corporation VCEL, a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan ...
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
CAMBRIDGE, Mass., Aug. 29, 2024 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the ...
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro - Vericel ( NASDAQ:VCEL )
CAMBRIDGE, Mass., Aug. 26, 2024 ( GLOBE NEWSWIRE ) -- Vericel Corporation VCEL, a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S.
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration ...
Autologous Cell Therapy Market Estimated to Grow USD 34.7 Billion by 2027, Rising at a 18.1% CAGR- Transparency Market Research, Inc.
Wilmington, Delaware, United States, Transparency Market Research Inc. , Aug. 21, 2024 ( GLOBE NEWSWIRE ) -- According to Transparency Market Research ( TMR ) , the global autologous cell therapy market value ( 다낭성 난소 증후군 치료 시장 ) is estimated to total US$ 34.7 Billion by the end of 2027 at a ...
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
Completed Construction of New NexoBrid® Manufacturing Facility €16.25 Million EIC FundingExpedites EscharEx® Development for Diabetic Foot Ulcers, Significantly Expanding the Addressable Market;Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by ...
Stem Cell Therapy Market to Surpass USD 28.60 Billion by 2031, Witnessing 11.2% CAGR Growth | SkyQuest Technology
Westford, USA, Aug. 09, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that Global Stem Cell Therapy Market will attain a value of USD 28.60 Billion by 2031, with a CAGR of 11.2% over the forecast period ( 2024-2031 ) .
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024 - Vericel ( NASDAQ:VCEL )
CAMBRIDGE, Mass., Aug. 07, 2024 ( GLOBE NEWSWIRE ) -- Vericel Corporation VCEL, a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Growth Conference at 3:00 p.m.
What Makes Vericel ( VCEL ) a New Strong Buy Stock
Vericel (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Apple To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Friday - Apple ( NASDAQ:AAPL ) , AerCap Holdings ( NYSE:AER )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JP Morgan cut the price target for Roku, Inc. ROKU from $90 to $80.
Vericel Corporation ( VCEL ) Reports Q2 Loss, Lags Revenue Estimates
Vericel (VCEL) delivered earnings and revenue surprises of 0% and 0.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Vericel Reports Second Quarter 2024 Financial Results
Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million ...
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
CAMBRIDGE, Mass., July 22, 2024 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi ...
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
CAMBRIDGE, Mass., July 18, 2024 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024.
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024 - Vericel ( NASDAQ:VCEL )
CAMBRIDGE, Mass., July 18, 2024 ( GLOBE NEWSWIRE ) -- Vericel Corporation VCEL, a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024.
Vericel ( NASDAQ:VCEL ) Downgraded by StockNews.com to Sell
StockNews.com cut shares of Vericel ( NASDAQ:VCEL - Free Report ) from a hold rating to a sell rating in a report issued on Tuesday. Several other analysts have also issued reports on the stock.
Vericel Scores Relative Strength Rating Upgrade; Hits Key Benchmark
Vericel Scores Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
Vericel ( NASDAQ:VCEL ) Upgraded to "Hold" at StockNews.com
StockNews.com upgraded shares of Vericel ( NASDAQ:VCEL - Free Report ) from a sell rating to a hold rating in a report published on Friday. Several other brokerages also recently weighed in on VCEL. Truist Financial restated a buy rating and set a $54.00 price objective on shares of Vericel in ...
Vericel Shows Rising Price Performance With Jump To 82 RS Rating
On Thursday, Vericel ( VCEL ) got an upgrade to its Relative Strength ( RS ) Rating, from 77 to 82. X IBD's proprietary rating measures share price performance with a 1 ( worst ) to 99 ( best ) score. The grade shows how a stock's price movement over the trailing 52 weeks holds up against all ...
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
CAMBRIDGE, Mass., June 11, 2024 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the ...
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
NexoBrid® interest surges. $5 million in Q1 2024 revenue, with $24 million forecast for the year ...
Vericel ( NASDAQ:VCEL ) Downgraded to Sell at StockNews.com
StockNews.com lowered shares of Vericel ( NASDAQ:VCEL - Free Report ) from a hold rating to a sell rating in a research report released on Monday.
Stem Cell Therapy Market size is set to grow by USD 11.65 billion from 2023-2027, Increasing prevalence of chronic ... - PR Newswire
Stem Cell Therapy Market size is set to grow by USD 11.65 billion from 2023-2027, Increasing prevalence of chronic ... PR ...
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
CAMBRIDGE, Mass., May 22, 2024 ( GLOBE NEWSWIRE ) -- Vericel Corporation ( NASDAQ:VCEL ) , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the ...
Invivyd Elects Two New Independent Members to its Board of Directors
WALTHAM, Mass., May 22, 2024 ( GLOBE NEWSWIRE ) -- Invivyd, Inc. ( Nasdaq: IVVD ) , a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that two new independent directors, Dr. Srishti Gupta and Kevin F.
Invivyd Elects Two New Independent Members to its Board of Directors - Invivyd ( NASDAQ:IVVD )
WALTHAM, Mass., May 22, 2024 ( GLOBE NEWSWIRE ) -- Invivyd, Inc. IVVD, a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that two new independent directors, Dr. Srishti Gupta and Kevin F.
